<DOC>
	<DOCNO>NCT00391014</DOCNO>
	<brief_summary>The trial plan multicentric , national , phase II , open-label trial evaluate safety tolerance nebulized Liposomal Amphotericin B ( Ambisome ) LMA patient induction therapy , intensification , plus Allogeneic Haematopoietic Progenitor Cell transplant due course , well patient diagnose several malignant haematologic disease treat Allogeneic Haematopoietic Progenitor Cell Transplant</brief_summary>
	<brief_title>Nebulized Liposomal Amphotericin B Ambisome Prophylaxis Invasive Pulmonary Aspergillosis</brief_title>
	<detailed_description>The invasive fungal infection ( IFI ) common cause mortality relate autologous stem cell transplant . Taking account Saprophytic Aspergillus usually acquire inhalation , protect bronchial tree tissue invasion quite attractive . In haematologic patient , well one subject Allogeneic haematopoietic progenitor cell transplant , another group patient high risk Invasive Pulmonary Aspergillosis ( IPA ) . These patient acute myeloid leucemia ( AML ) , submit induction , intensification consolidation polychemotherapy . The IPA incidence rate patient , whenever evolution , reach 18-20 % , usual treatment . Furthermore , unlike allogeneic haematopoietic progenitor cell transplant patient , neutropenia IPA risk factor . Nowadays , pharmacologic prophylaxis IPA , patient allogeneic haematopoietic progenitor cell transplant patient affect AML induction intensification therapy far optimal , problem related tolerance drug interaction . The Nebulized Liposomal Amphotericin B ( Ambisome ) prophylaxis IPA show good tolerance , safety efficacy lung transplant recipient . Extrapolating result obtain lung transplant recipient , get conclusion would essential study safety tolerance nebulized AMBISOME group patient different peculiarity , mucositis secondary chemotherapy , high incidence IPA order reach goal evaluate efficacy prophylaxis IPA kind patient</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Patient decide voluntary consent participation sign consent form performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Patients Acute myeloid Leukemia ( AML ) , start induction chemotherapy patient submit Allogeneic haematopoietic progenitor cell transplant . The patient &gt; 18 year old . Patient prior Invasive Pulmonary Aspergillosis ( IPA ) history . History allergy hypersensitivity Amphotericin B . Patient intellectual deficit patient psychological alteration make impossible trial understanding . Pregnancy breastfeed . Patient receive investigational drug non trade product within 30 day trial beginning . Patient enrol another clinical research study or/and receive investigational agent reason . Patient major surgery within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Acute myeloid Leukemia</keyword>
	<keyword>Allogeneic haematopoietic progenitor cell transplant</keyword>
	<keyword>Acute Invasive Aspergillosis</keyword>
</DOC>